|March 2015 Working Paper:
Antiretroviral Priorities of the Medicines Patent Pool – Fourth Edition
Comments welcome and encouraged. Please mail input to gro.looptnetapsenicidemnull@eciffo with subject line “Comments on ARV Priorities of the MPP – Working Paper”
The Medicines Patent Pool focuses on increasing access to HIV medicines. As the HIV medicines landscape is in constant evolution, the priorities of the MPP must be revised on a regular basis. The HIV medicines currently targeted for inclusion in the Medicines Patent Pool are chosen based on ongoing consultation with a wide variety of HIV experts. The Antiretroviral Priorities of the Medicines Patent Pool, revised and updated annually, set the priorities of the MPP taking into consideration recent developments in the clinical, market and intellectual property landscape for different ARVs. Target medicines include those already in the market as well as antiretrovirals that are currently in late-stage clinical development. The working paper is a living document currently in its fourth edition. Comments are both welcome and encouraged.
Current target products and formulations:
The MPP prioritises target medicines based on two criteria: the medicine’s clinical importance (determined in consultation with medical and public health experts) and the extent to which the medicine is patented in developing countries (market/IP priority). Each drug is assigned a level of priority: high, medium, or low.
|PRODUCTS NOT YET LICENSED TO THE MPP|
|ARV||CLINICAL PRIORITY||MARKET/IP PRIORITY|
|PRODUCTS ALREADY LICENSED TO THE MPP|
|ARV||DATE ADULT LICENCE||DATE PAEDIATRIC LICENCE|
|Abacavir (ABC)||July 2014||February 2013|
|Atazanavir (ATV)||December 2013||December 2013|
|Cobicistat (COBI)||July 2011||July 2011|
|Darunavir (DRV)‡ ‡ ‡||September 2010||September 2010|
|Dolutegravir (DTG)||April 2014||April 2014|
|Elvitegravir (EVG)||July 2011||July 2011|
|Emtricitabine (FTC)||July 2011||July 2011|
|Lopinavir (LPV)||December 2014|
|Raltegravir (RAL)||February 2015|
|Ritonavir (RTV)||December 2014|
|Tenofovir alafenamide (TAF)||July 2014||July 2014|
|Tenofovir disoproxil fumarate (TDF)||July 2014||July 2014|
|TDF/FTC/EFV||June 2015||June 2015|
* Licensed to the MPP for paediatric use
# Discussion ongoing for inclusion in current MPP licences
‡ ‡ ‡ In September 2010, the MPP obtained a licence on darunavir-related patents from the US National Institutes of Health. At the time, however, there were other patents on DRV held by other patent holders.
The table above is based on the Antiretroviral Priorities of the Medicines Patent Pool [pdf].
Previous editions of the working paper are available here.